• Home
  • Artificial Intelligence
  • Cryptocurrencies
  • Technology
  • Gold
  • Stocks
    RedditBluesky
    • Home
    • Artificial Intelligence
    • Cryptocurrencies
    • Technology
    • Gold
    • Stocks
    Home » News » "Best cannabis in the world"

    "Best cannabis in the world"

    Member from House of Representatives in favor of legal weed

    Justin Wong (JW)May 9, 2025



    Nancy Mace started using marijuana after she was raped in high school. "There was no light in my life," Mace told Yahoo News of that time. "I dropped out of school and became a waitress at the Waffle House.

    Eventually, she returned to school with renewed determination, and in 1999 became the first woman to graduate from the Citadel. After working in South Carolina politics, she was elected a Republican to the US House of Representatives in 2018, becoming only the second woman to represent the state in Washington.

    Now she's using her newfound influence nationally to campaign for the legalization of the drug that helped her overcome the trauma of a sexual assault, with a law that decriminalizes the drug and taxes it, with one a three percent "sin tax" (also known as an excise tax), similar to what formerly applied to tobacco and alcohol. With the so-called "States Reform Act" cannabis would be treated like alcohol and not like heroin.

    "When you poll this issue and put it on the ballot, there is overwhelming support regardless of political affiliation," Mace said in a recent interview with Yahoo News. In fact, cannabis legalization seems to be the least controversial issue in a controversy-torn society. A recent Pew poll shows that 91 percent of Americans support legalization.

    Cannabis (the word "marijuana" has fallen out of favor, in part because of its racial connotations) is already legal for medical use in 37 states; 18 states also allow recreational use. However, the federal government still puts the drug in the same category as LSD and ecstasy, making it difficult even in states where cannabis is legal to obtain essential functions like banking for pharmacies.

    Mace's proposal is one of several cannabis-related proposals currently being considered by Congress. An obstacle to much of this legislation is Senate Majority Leader Chuck Schumer, who has his own ambitious cannabis reform bill that he prefers to more modest proposals that would, for example, make it easier for cannabis-related businesses to use the federal banking system.

    Schumer even removed a banking-related provision from last year's defense bill, angering House members who introduced and supported the measure. "I don't really know what his problem is," Rep. Jim McGovern (Massachusetts) said of Schumer at the time.

    Proponents continue their argument, seeing the democratic control of Congress as an excellent opportunity for action. But with the coronavirus pandemic disrupting the normal course of the legislature and other progressive priorities, it's not obvious that cannabis is getting the hearing it deserves. A Bloomberg analyst described interest in reform as "lukewarm".

    Mace says Democrats have committed to a hearing on their bill that would allow states to regulate cannabis at their discretion. "He'll be the tastiest for both parties," she told Yahoo News.

    The cultural-political aspects of the issue are intriguing, putting a traditional conservative like Mace in the same boat as libertarian Sen. Rand Paul (R-Ky.) and progressive Rep. Alexandria Ocasio-Cortez (D-N.Y.). Last year, the White House came under fire for firing five employees who admitted to having used cannabis in the past.

    The issue is far less popular with Republicans (47 percent agree, according to Pew) than Democrats (72 percent), meaning Mace's position is not without risk. The issue is nowhere near as politically settled in South Carolina as it is in some other states, where legalization is a hotly contested issue in the upcoming gubernatorial race.

    After introducing the bill, Mace was rebuked by the South Carolina Republican Party leader, who denounced "any effort to legalize or decriminalize the use of controlled substances."

    Mace says she's not afraid to go it alone, although some Republicans in the House of Representatives support her proposal. "If you do that, you'll never get anywhere," she told Yahoo News.

    In her short time in Washington, Mace has blazed her own trail several times, charting a course that is neither slavish to Trump nor committed to the Kinzinger-Cheney model of internal resistance. She's clashed with both Ocasio-Cortez and MAGA-loyal Rep. Marjorie Taylor Greene, whom she dismissed with a classic Southern quip: "Bless her f***ing heart."

    While that kind of rhetoric has grabbed headlines, it hasn't necessarily endeared itself to the GOP leadership. "I don't really understand the game she's playing," one congressman admitted to Politico last fall.

    The complex cross-currents of the moment could bring Mace an unexpected victory as both parties need something to campaign with in the fall. But the same dynamic could also leave Mace with a failed bill that draws Republican enmity while unloved by moderate Democrats.

    Still, the effort was given a big boost last month by support from Amazon, which has become increasingly involved in Washington affairs (founder Jeff Bezos owns the Washington Post as well as the largest residence in the county). "Like so many in this country, we believe it is time to reform the nation's cannabis policy and Amazon is committed to leading the effort," tweeted an account linked to the company's lobbying efforts.

    It's a single tweet, but one that represents a corporate giant settling in Northern Virginia. The news gave Mace's proposal "a lot of momentum going into the beginning of this year," she said. "I foresee other companies being encouraged to support the bill. Given the cultural standing of giants like Amazon, such corporate commitments could prove more promising for their bill than pleas from activists in other efforts.

    So far, however, drug reform efforts have been concentrated at the state level and there is little evidence of national policy. Maine is in the process of decriminalizing psilocybin (better known as "magic mushrooms"), which the District of Columbia decriminalized last year. There are even moves to legalize LSD, as evidence mounts that psychedelic drugs - long caricatured as a hippie habit - can successfully treat some serious mental illnesses.

    About half of all Americans have tried cannabis in some form, and while concerns remain about its heavy use by youth, cannabinoids - the psychoactive compounds in the buds of the cannabis plant - also appear to help with a range of ailments. Mace reports that she recently spoke to a mother whose 14-year-old daughter has cerebral palsy and has a series of seizures every day. Cannabis helps, even in the "trace amounts" the mother says she administered.

    "We have the best cannabis in the world," she says of the United States, imagining a kind of boom akin to that of the dying American wine industry that began after California vintages outperformed their continental counterparts at a famous 1976 tasting in Paris. "Let's start here."

    USACannabisRegierung





    Disclaimer


    This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

    Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

    This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

    Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

    The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

    Information about the editor of this publication:
    Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

    Note on copyright:
    The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.


    Claw and Order: Antimony Rules the Resource Realm
    Read Next

    Claw and Order: Antimony Rules the Resource Realm

    • RIDE THE BULL

      Your Front Row Seat to the Stories That Move Markets. – Subscribe Now to our Newsletter!

    • Trending Now

      • Mario Vetro’s Axcap Ventures: Drilling Holes in Junior Mining’s Problems
        Mario Vetro’s Axcap Ventures: Drilling Holes in Junior Mining’s Problems
      • Stocks Pop as Trump Drops “Buy Now” Like It’s Hot
        Stocks Pop as Trump Drops “Buy Now” Like It’s Hot
      • The AI Tug-of-War: Can America Hold the Line Against China?
        The AI Tug-of-War: Can America Hold the Line Against China?
      • Bitcoin’s $99K Moonshot: Trump’s the Rocket Fuel
        Bitcoin’s $99K Moonshot: Trump’s the Rocket Fuel

    Claim Your Spot with Juniorstocks.com

    Unlock the stories that move markets directly in your inbox


    ContactDisclaimerData PrivacyTerms of Use
    • Bluesky
    • Reddit
    Copyright 2025 ©Juniorstocks.com - All Rights Reserved.
    Press enter/return to begin your search